Clinical Trials Browser

Turcot syndrome, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06980350 2025-07-29

Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy

Completed

156 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

Phase 2 Not yet recruiting

28 enrolled

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT06543836 2024-08-09

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Phase 2 Recruiting

68 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04715633 2024-07-09

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Phase 2 Active not recruiting

53 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06321081 2024-03-20

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06031376 2023-09-11

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Completed

106 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06011330 2023-08-30

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

Completed

70 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05371197 2022-05-12

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Phase 2 Unknown

26 enrolled

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

Clinical Trials

SYLVER

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer